Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Finished Goods: 2024-2025

Historic Finished Goods for Syndax Pharmaceuticals (SNDX) over the last 1 years, with Sep 2025 value amounting to $2.2 million.

  • Syndax Pharmaceuticals' Finished Goods was N/A to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $36,000 for FY2024, which is N/A change from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Finished Goods stood at $2.2 million for Q3 2025, which was down 1.34% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Finished Goods peaked at $2.3 million during Q1 2025, and registered a low of $36,000 during Q4 2024.
  • Its 2-year average for Finished Goods is $1.7 million, with a median of $2.2 million in 2025.